FRANKFURT (Reuters) - German drugmaker Bayer said on Friday it requested approval from U.S. regulators for an experimental prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.
Radium-223 dichloride, which Bayer used to call Alpharadin, is designed to target bone metastases from prostate cancer that cannot be treated by standard hormone therapy.
On Wednesday, Bayer said it was requesting EU approval for the drug.
Bayer said last year that Radium-223 dichloride could become a “blockbuster” product with annual sales of least 1 billion euros.
The drug has some properties of calcium, which makes it cling to cancerous bone cells and then destroy them via alpha rays, which is more targeted that the shotgun approach of conventional radiotherapy.
Reporting by Jonathan Gould